Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
umbilical cord mesenchymal stem cells (The Fifth Medical Center of the PLA General Hospital)
- Development stage
- Unknown
- Lead developer
- The Fifth Medical Center of the PLA General Hospital
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
This experimental cell therapy consists of human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) isolated from Wharton's jelly. Developed by Fu-Sheng Wang and colleagues at the Fifth Medical Center of Chinese PLA General Hospital, it is specifically investigated for HIV-infected immune non-responders (INRs)—patients who fail to achieve sufficient CD4+ T cell recovery despite effective viral suppression through antiretroviral therapy (ART). The therapy functions by modulating the host's immune response and suppressing chronic inflammation and aberrant immune activation, which are key drivers of T cell depletion in chronic HIV infection. Results from a Phase 2 randomized, double-blind, placebo-controlled trial (NCT01213186) indicated that intravenous administration of these MSCs is safe and leads to a significant increase in CD4+ T cell counts, suggesting a potential role in immune reconstitution for this patient population.
- Other names
- human umbilical cord-derived mesenchymal stem cellsWharton's jelly-derived mesenchymal stem cells
Beyond the preview
Go deeper on umbilical cord mesenchymal stem cells (The Fifth Medical Center of the PLA General Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on umbilical cord mesenchymal stem cells (The Fifth Medical Center of the PLA General Hospital).